Key Insights

Highlights

Success Rate

95% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

4.0%

1 terminated out of 25 trials

Success Rate

95.2%

+8.7% vs benchmark

Late-Stage Pipeline

20%

5 trials in Phase 3/4

Results Transparency

10%

2 of 20 completed with results

Key Signals

2 with results95% success

Data Visualizations

Phase Distribution

18Total
Not Applicable (8)
P 1 (3)
P 2 (2)
P 3 (1)
P 4 (4)

Trial Status

Completed20
Withdrawn1
Unknown1
Not Yet Recruiting1
Recruiting1
Terminated1

Trial Success Rate

95.2%

Benchmark: 86.5%

Based on 20 completed trials

Clinical Trials (25)

Showing 20 of 20 trials
NCT07002047CompletedPrimary

Real World and Epidemiology Study of Medically Attended Chlamydia Trachomatis Among Adults in Germany

NCT07458802Not ApplicableNot Yet Recruiting

Healthy Expectancy Through Routine Antenatal STI Screening

NCT06216964Not ApplicableRecruitingPrimary

Time to Clearance of Chlamydia Trachomatis and Neisseria Gonorrhoeae RNA After Treatment: a Prospective Cohort Study

NCT04446611Not ApplicableCompleted

Clinical Study of STI Screening to Prevent Adverse Birth and New-born Outcomes (Philani Ndiphile)

NCT00207454Phase 1CompletedPrimary

Optimizing Strategies to Improve STD Partner Services

NCT03676816Not ApplicableCompletedPrimary

Self Sampling for Rapid Turnaround Testing in the Emergency Department

NCT02391233Not ApplicableCompleted

Multimedia WORTH With Black Drug-Involved Women on Probation

NCT03071510CompletedPrimary

Evaluation of the Atlas Genetics io® CTNG System

NCT00213031Phase 2Completed

Safety, Acceptability and Preliminary Effectiveness of PC-515 for Vaginal Use as a Possible Microbicide

NCT00213018Phase 2Completed

Safety, Acceptability and Preliminary Effectiveness of Carraguard™ (PC-515) in Preventing HIV/STI Transmission

NCT00213057Phase 1Completed

Safety and Acceptability of Carraguard™ Among HIV-negative Couples in Thailand

NCT02787109Phase 1CompletedPrimary

Safety of Chlamydia Vaccine CTH522 in Healthy Women Aged 18 to 45 Years

NCT02795975TerminatedPrimary

Clinical Evaluation of the Aptima® Combo 2® Assay Using the Panther® System in Female Urine Samples

NCT00978848Completed

Non-Invasive Sexually Transmitted Disease Testing in Women Seeking Emergency Contraception or Urine Pregnancy Testing

NCT02128620Not ApplicableCompleted

A Randomized Online Health Experiment for a Safer Youth Sexual Behaviour

NCT01661985Phase 4Unknown

Time to Eradication of Mycoplasma Genitalium and Chlamydia Trachomatis After Treatment Commenced

NCT01733069CompletedPrimary

Clinical Evaluation of the APTIMA® COMBO 2® Assay Using the PANTHER™ System

NCT01358799WithdrawnPrimary

Clinical Evaluation of the APTIMA® Assay for Chlamydia Trachomatis Using the PANTHER™ System

NCT01329588Phase 4Completed

Periodical Presumptive Treatment for the Control of Gonococcal Infections Among Sex Workers

NCT01665690Phase 4Completed

Washington State Community Expedited Partner Treatment (EPT) Trial

Scroll to load more

Research Network

Activity Timeline